Runze Wang 🚀

Runze Wang

Undergraduate, Clinical Laboratory

Hangzhou Medical College

Professional Summary

Runze Wang is an undergraduate student at Hangzhou Medical College, where he participated in an AI-augmented antivirulence therapy project against Clostridioides difficile. As first author in Journal of Medicinal Chemistry (2025) and co-author in Communication Biology (2025), his work has revealed pan-subtype small-molecule neutralizers of toxin B. Wang is the inventor on three pending national patents, creator of the open-source VortexDock distributed docking suite (⭐80+ GitHub stars), and Student PI of a national undergraduate innovation grant.
He integrates mathematics, computer science, and biology to drive research in computational chemistry, microbiology, pharmacology, structural biology, biostatistics, and machine learning.

Education

BS Clinical Laboratory

Hangzhou Medical College

Interests

Host-pathogen Interactions Medicinal Chemistry Mathematical Modeling Machine Learning
📚 My Research
My research officially centers on Host–pathogen interaction, focusing on Clostridioides difficile toxin B (TcdB). By merging computational chemistry, microbiology, pharmacology, and AI-driven drug design, I mapped TcdB’s receptor divergence, built virtual-screening pipelines for pan-subtype neutralizers, validated hits via MD, CD, SPR, and advanced candidates into animal models, securing first-author paper in J. Med. Chem. and co-author in Commun. Biol., three patents as inventor, and an open-source docking suite.
Featured Publications

Biliverdin targeting TcdB-DRBD inhibits Clostridioides difficile virulence and restores gut microbiota in Mongolian gerbils (Meriones unguiculatus)

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis posuere tellus ac convallis placerat. Proin tincidunt magna sed ex sollicitudin condimentum.

Shuangshuang Wan
Read more

Virtual Screening and Multistage Computational Profiling of Small-Molecule Inhibitors Targeting Clostridioides difficile Toxin B

Dirlotapide represents a rapidly repositionable anti-TcdB agent that neutralizes clinically relevant subtypes through dual RBI blockade, and validation of gut-restricted …

avatar
Runze Wang
Read more
Recent Publications & Patents
(2025). Biliverdin targeting TcdB-DRBD inhibits Clostridioides difficile virulence and restores gut microbiota in Mongolian gerbils (Meriones unguiculatus). Communication Biology, 2025, 68, 19, 20389–20409.
(2025). Virtual Screening and Multistage Computational Profiling of Small-Molecule Inhibitors Targeting Clostridioides difficile Toxin B. Journal of Medicinal Chemistry, 2025, 68, 19, 20389–20409.
(2025). Non-antibiotic small molecule inhibitors of Clostridioides difficile toxin B and screening methods thereof. Chinese Patent Application CN202510777443.X. Hangzhou Medical College.
(2025). Application of pranlukast in preparing anti-Clostridioides difficile infection drugs. Chinese Patent Application CN202510715258.8. Hangzhou Medical College.
(2025). Method for identifying silkworm sulfakinin receptor. Chinese Patent Application CN202510380413.5. Hangzhou Medical College.
Recent Blogs